InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...
Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
Leerink Partners Global Healthcare Conference March 8 - 11, 2026 in Miami, FL Fireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view ...
Complement represents a chief component of innate immunity in host defense. However, excessive complement activation has been involved in the pathogenesis of inflammatory diseases. In this study, we ...
Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...
C5aR1 expression correlates with increased metastasis risk and poor survival in cSCC patients. The tumor microenvironment, especially fibroblasts, influences C5aR1 expression and cSCC progression.
The complement system is a central component of innate immunity, consisting of a large family of plasma and membrane bound proteins that are critical for protection against bacterial infection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results